<DOC>
	<DOCNO>NCT02956772</DOCNO>
	<brief_summary>A multicentre , randomize , open-label , parallel-group , active control study .</brief_summary>
	<brief_title>Transcatheter Arterial Chemoembolization ( TACE ) Combination With Arsenic Trioxide Versus TACE Treatment Middle-advanced Primary Hepatocellular Carcinoma ( HCC ) Patients</brief_title>
	<detailed_description>Primary hepatocellular carcinoma ( HCC ) one common type cancer account significant morbidity mortality worldwide . Notably , half new HCC case death develop China . Transarterial chemoembolization ( TACE ) propose first-line therapeutic strategy treatment patient unresectable HCC . However , TACE several limitation might potentially associate tumor metastasis relapse . Recent study demonstrate arsenic trioxide ( As2O3 ) act first-line therapeutic option treatment acute promyelocytic leukemia . Thereafter , several small study China show promising clinical benefit As2O3 administrate among HCC patient . With preliminary result , investigator plan carry multicenter randomize control trial explore potential efficacy safety adjuvant As2O3 treatment HCC patient .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>1 . Subject 1880 year old . 2 . Subject portal stem vein tumor thrombus . 3 . Subject primary middleadvanced liver cancer Barcelona Clinic Liver Cancer stag B/C inappropriate surgical resection locoregional therapy still present tumor lesion liver . 4 . Subject evaluable tumor lesion ( ) ( use Magnetic Resonance Imaging /Computed Tomography ) accord modify Response Evaluation Criteria Solid Tumors ( mRECIST ) Version 1.1 : single lesion size ≥5cm least one lesion &gt; 3cm size 23 lesion exist 4 lesion . 5 . Subject Eastern Cooperative Oncology Group ( ECOG ) performance status ≤1 , Fibrosis index base 4 factor ( FIB4 ) ≤6 expect survival time 12 week . 6 . Haematology : white blood cell count ≥3.0×10^9/L ; hemoglobin≥10 g/dL ; blood platelet count≥80×10^9/L 7 . Blood biochemistry : serum albumin ≥2.8 g/dL , total bilirubin ≤2 mg/dL ≤34.2 umol/L , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2 time upper limit normal ( ULN ) ; amylase lipase ≤ 1.5 time ULN ; serum creatinine ≤2.0 mg/dL &lt; 1.5 time ULN ; estimate creatinine clearance ≥60 mL/min . 8. International normalize ratio ( INR ) ≤ 2.3 prothrombin time ( PT ) ≤3 second upper limit normal control . 9 . Echocardiogram indicate leave ventricular ejection fraction ( LVEF ) &gt; 50 % . 10 . Subject liver function ChildPugh class A B . 11 . Subject pregnant lactating . 12 . Female subject must infertile agree take effective contraceptive ; male subject partner reproductive potential must also agree use appropriate contraceptive . 13 . Subject second tumor last 5 year , exclude skin basal cell carcinoma skin squamous carcinoma carcinoma situ . 14 . Subject history systemic chemotherapy . 15 . Subject concomitant anticancer therapy , local radiotherapy , systemic chemotherapy molecular target therapy . 16 . Subject ( ) guardian able understand study willing provide write , inform consent participate clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>